Updating {{drugbox}} (changes to watched fields - updated 'DrugBank_Ref', 'ChEBI_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or bugs) |
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot |
||
Line 1: | Line 1: | ||
{{ |
{{Drugbox |
||
| Watchedfields = changed |
| Watchedfields = changed |
||
| verifiedrevid = 408993506 |
| verifiedrevid = 408993506 |
||
|IUPAC_name= 4-(2-((1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-ylamino)ethyl)phenol |
| IUPAC_name = 4-(2-((1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-ylamino)ethyl)phenol |
||
|image=Ritodrine2.png |
| image = Ritodrine2.png |
||
⚫ | |||
<!--Clinical data--> |
|||
| tradename = |
|||
| Drugs.com = {{drugs.com|CONS|ritodrine}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Pharmacokinetic data--> |
|||
⚫ | |||
⚫ | |||
<!--Identifiers--> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = 30971 |
| ChemSpiderID = 30971 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = I0Q6O6740J |
| UNII = I0Q6O6740J |
||
⚫ | |||
⚫ | |||
| KEGG_Ref = {{keggcite|correct|kegg}} |
| KEGG_Ref = {{keggcite|correct|kegg}} |
||
| KEGG = D02359 |
| KEGG = D02359 |
||
⚫ | |||
⚫ | |||
<!--Chemical data--> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
| InChI = 1/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1 |
| InChI = 1/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1 |
||
| InChIKey = IOVGROKTTNBUGK-SJCJKPOMBT |
| InChIKey = IOVGROKTTNBUGK-SJCJKPOMBT |
||
Line 19: | Line 46: | ||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChIKey = IOVGROKTTNBUGK-SJCJKPOMSA-N |
| StdInChIKey = IOVGROKTTNBUGK-SJCJKPOMSA-N |
||
⚫ | |||
⚫ | |||
⚫ | |||
|ATC_supplemental= |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
|bioavailability= |
|||
⚫ | |||
|metabolism= |
|||
⚫ | |||
|excretion= |
|||
⚫ | |||
⚫ | |||
|pregnancy_category= |
|||
⚫ | |||
⚫ | |||
⚫ | |||
|legal_status= |
|||
⚫ | |||
}} |
}} |
||
Revision as of 21:54, 30 August 2011
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Oral, parenteral |
ATC code | |
Pharmacokinetic data | |
Protein binding | ~56% |
Elimination half-life | 1.7-2.6 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.043.512 |
Chemical and physical data | |
Formula | C17H21NO3 |
Molar mass | 287.354 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ritodrine (trade name Yutopar) is a tocolytic drug, was used to stop premature labor.[1] It is available in oral tablets or as an injection, and is typically used as the hydrochloride salt, ritodrine hydrochloride. This drug has been removed from the market.
Mechanism
Ritodrine is a beta-2 adrenergic receptor agonist - a class of medication used for smooth muscle relaxation (other similar drugs are used in asthma or other pulmonary diseases such as salbutamol). Since ritodrine has a bulky N-substituent, it has high β2-selectivity. Also, the 4'-hydroxy on the benzene ring is important for activity as it is needed to form hydrogen bonds. However, the 4'-hydroxy makes it susceptible to metabolism by COMT. Since it is β2-selective it is used for premature labor.[2]
Side effects and potential contraindications
Most side effects of beta-2 agonists result from their concurrent beta-1 activity, and include increase in heart rate, rise in systolic pressure, decrease in diastolic pressure, chest pain secondary to MI, and arrhythmia. Beta agonists may also cause fluid retention secondary to decrease in water clearance, which when added to the tachycardia and increased myocardial work, may result in cardiac failure. In addition, they increase gluconeogenesis in the liver and muscle resulting in hyperglycemia, which increases insulin requirements in diabetic patients. The passage of beta-agonists through the placenta does occur and may be responsible for fetal tachycardia, as well as hypoglycemia or hyperglycemia at birth.
Patients with type 2 diabetes, high blood pressure or migraines should bring this to their doctor's attention before receiving care.
It has also been associated with post-partum hemorrhage.[citation needed]
References
- ^ Li X, Zhang Y, Shi Z (2005). "Ritodrine in the treatment of preterm labour: a meta-analysis" (PDF). The Indian journal of medical research. 121 (2): 120–7. PMID 15756046.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Medicinal Chemistry of Adrenergics and Cholinergics